Q-omics provides the consensus-scored AZGP1 profile across patient tissues and cancer cell-line models. AZGP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AZGP1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, AZGP1 protein abundance shows 25,864 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRP, and PDAC as cancer lineages where AZGP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AZGP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AZGP1 survival associations across molecular data types. AZGP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AZGP1 RNA expression–survival associations across cancer types. High AZGP1 expression shows unfavorable associations in LUAD and THCA, but favorable associations in UVM, KIRP, KIRC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AZGP1 RNA expression.
This table summarizes AZGP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AZGP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AZGP1 shows lower tumor expression in KIRP, HNSC, LIHC, LUSC and BLCA and higher tumor expression in COAD. The KIRP box plot shows higher AZGP1 RNA expression in normal versus tumor tissue (log2 FC = −3.668, t-test p < 0.001).
This table shows molecular features associated with AZGP1 in patient tissues and cancer cell lines. In patient samples, AZGP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, AZGP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
